Melissa Redding, PA
Medical · Oklahoma City, OKNPI 1831588623
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,533 and has fallen 63.1% since, to $566 in 2025.
Across 254 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$978
- Amgen$754
- Bayer$487
- Otsuka America Pharmaceutical, Inc.$429
- OPKO Pharmaceuticals, LLC$281
- Fresenius USA Marketing, Inc.$256
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,18399%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 42 | $978 |
| Amgen(2 entities) | 37 | $754 |
| Bayer | 27 | $487 |
| Otsuka America Pharmaceutical, Inc. | 20 | $429 |
| OPKO Pharmaceuticals, LLC | 20 | $281 |
| Fresenius USA Marketing, Inc. | 21 | $256 |
| Daiichi Sankyo Inc. | 12 | $237 |
| Veloxis Pharmaceuticals, Inc. | 7 | $211 |
| Boehringer Ingelheim | 6 | $209 |
| Vifor Pharma, Inc. | 11 | $208 |
| Pharmacosmos Therapeutics Inc. | 8 | $188 |
| Travere Therapeutics, Inc. | 2 | $155 |
| Aurinia Pharma U.S., Inc. | 7 | $153 |
| Calliditas Therapeutics US Inc. | 6 | $131 |
| Ardelyx, Inc. | 5 | $85 |
| ANI Pharmaceuticals, Inc. | 3 | $76 |
| Novo Nordisk | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Akebia Therapeutics Inc | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 2 | $55 |
| GSK | 3 | $40 |
| Cormedix Inc. | 1 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,249 in reported general payments places this provider in the 85th percentile of 370 medical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical in Oklahoma City
- Mebin ThomasOklahoma City$323K
- Kristine MurrowOklahoma City$81K
- Katelyn PuryearOklahoma City$22K
- Kelly WalworthOklahoma City$15K
- Jere ClaunchOklahoma City$15K
- Vy TranOklahoma City$15K
- Jennifer MinshallOklahoma City$11K
- Lindee LedbetterOklahoma City$10K
- Christina HelmsOklahoma City$7K
- John ParmeleeOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.